NCT05486546 Contoura With Phorcides Compared to Wavefront Optimized LASIK
| NCT ID | NCT05486546 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Daniel Terveen |
| Condition | Myopia |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2022-08-15 |
| Primary Completion | 2023-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2022-08-15 with a primary completion date of 2023-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Comparing post-operative visual acuity and patient reported satisfaction between Contoura with Phorcides and WaveLight Wavefront Optimized.
Eligibility Criteria
Inclusion Criteria: * Patients at least age 21 years of age undergoing LASIK eye surgery * Willing and able to comprehend informed consent and complete 1 month post-op visit * Potential postoperative BCDVA of 20/20 or better in each eye based on Investigator's medical opinion * Candidates for Contoura with Phorcides (Myopic, astigmatism \<3.0D) * Both eyes targeted for plano * Pre-operative total corneal Pachymetry 490um or above * Stable refractive error \<0.50D change in preceding year * Good general and ocular health * Pre-operative exam completed within three months of surgery * SCL discontinued 3 days prior to pre-op exam and the procedure * Pachymetry above 490 with residual greater than 270um * Candidates who, as determined by the investigator, can safely undergo LASIK Exclusion Criteria: * Patients under 21 years of age * Concomitant ocular condition which would limit the BCVA at the discretion of the surgeon * Patients with usual relative and absolute contraindications for LASIK surgery (Patients with severe dry eye, recurrent corneal erosion, uncontrolled Glaucoma, collagen vascular disorders, keratoconus or signs of keratoconus, uncontrolled Diabetes, Herpes) * Pachymetry below 490 * Autoimmune or immunodeficiency diseases * Pregnant or nursing women * Patients with signs of inability to understand consent for study and procedure planned * Patients with history of previous ocular surgery * Patients with strabismus or amblyopia * Patients that have a BCDVA of 20/25 or worse in either eye
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05486546 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 38 Years, studying Myopia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05486546 currently recruiting?
Yes, NCT05486546 is actively recruiting participants. Contact the research team at daniel.terveen@vancethompsonvision.com for enrollment information.
Where is the NCT05486546 trial being conducted?
This trial is being conducted at Bozeman, United States, Omaha, United States, Fargo, United States, Sioux Falls, United States.
Who is sponsoring the NCT05486546 clinical trial?
NCT05486546 is sponsored by Daniel Terveen. The trial plans to enroll 120 participants.